



Combating diabetes



Organisation / Contact :

Yann de Boysson, Mellitech, Grenoble (France)

y.deboysson@mellitech.com, +0033 (0)6 76 39 57 87

Mellitech : SME dedicated to developing :

- new drugs for the treatment of type II diabetes
- bio-tools to enhance diabetes research, through better beta cell comprehension and manipulation (monoclonal antibody) and an animal model for type I

Mellitech is conducting R&D based on a new patented pharmacological target of the pancreatic beta cell



Combating diabetes



Thematic priority: TP1 LifeSciences, genomics and Biotechnology for health

Projects titles :

1. Molecular pathways underlying decreased beta cell mass in diabetes mellitus
2. Strategies for type1 diabetes

Status : under preparation

Call : 4

Instrument: STREP

Research area : combating major diseases

Topic : Applications-orientated genomic approaches to medical knowledge and technologies



Combating diabetes



Consortium : not evaluated yet

Project description & strategy: Mellitech aims at joining consortium that is interested in an expertise on a new protein involved in insulin secretion, cell protection against oxidative stress and apoptosis.

1. Molecular pathways underlying decreased beta cell mass in diabetes mellitus : our technology has potential for beta cell mass protection and functionality
2. Strategies for type1 diabetes : our technology enables developments based on polymorphisms, auto-immunity, stem cell differentiation, preparation and quality control of Langerhans islets

Partners sought : SMEs or laboratories involved in diabetes research